LC-MS And Biotech Expansion Will Unlock Secular Healthcare Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 15 Analysts
Published
10 Aug 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$428.45
32.5% undervalued intrinsic discount15 Aug
US$289.40
1Y
-14.9%7D
3.6%